EUVIMEDOpdag EUVIMED
FallberichtOpen access · CC BY 4.0

Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome

Agni M Konitsioti iD, Rafael Grajewski, Mark Schlamann, Michael Schroeter, Gereon R Fink, Clemens Warnke

European Journal of Neurology · 2025-03 · 32 (3)

DOI: 10.1111/ene.70103 ↗

At a glance

Fallbericht in European Journal of Neurology, published online on 2025-03-03. Written by Agni M Konitsioti and 5 co-authors. Institution: Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Major MEDLINE topics: Susac Syndrome, Natalizumab. Cited 4 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Susac syndrome is a rare autoimmune endotheliopathy that affects the central nervous system, retina, and inner ear, characterized by encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. Due to the heterogeneity of its presentation, early diagnosis, and treatment remain challenging. Objective/Methods To evaluate the clinical outcomes and radiological responses in two patients with Susac syndrome treated with natalizumab in an off‐label therapeutic approach, clinical assessments and serial magnetic resonance imaging (MRI) were performed over a follow‐up period of up to 22 months to monitor disease progression and treatment response.

Results

Both patients demonstrated clinical stabilization with reduced MRI and retinal angiography disease activity. Treatment was well tolerated, and no significant adverse events were reported during observation.

Discussion

Natalizumab may constitute a potential off‐label therapeutic for Susac syndrome. Further studies are warranted to assess its efficacy and safety in this rare condition.

Subjects

MeSH terms (MEDLINE)

Susac SyndromeNatalizumabHumansFemaleAdultMagnetic Resonance ImagingTreatment Outcome

Author keywords

DMTMRIneuroimmunologyneuroinflammationneuroopthalmologysusacvasculitis

Substances

Natalizumab

Authors and institutions

  • Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Department of Ophthalmology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Department of Radiology and Neuroradiology, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
  • Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM3), Research Center Jülich, Jülich, Germany.
  • Department of Neurology, University Hospital Marburg, Marburg, Germany.

ORCID profiles: Agni M Konitsioti

Cite

APA

Konitsioti, A. M., Grajewski, R., Schlamann, M., Schroeter, M., Fink, G. R., & Warnke, C. (2025). Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome. European Journal of Neurology, 32(3). https://doi.org/10.1111/ene.70103

Vancouver

Konitsioti AM, Grajewski R, Schlamann M, Schroeter M, Fink GR, Warnke C. Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome. European Journal of Neurology. 2025;32(3). doi:10.1111/ene.70103

BibTeX
@article{Konitsioti2025,
  author = {Konitsioti, Agni M and Grajewski, Rafael and Schlamann, Mark and Schroeter, Michael and Fink, Gereon R and Warnke, Clemens},
  title = {Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {3},
  doi = {10.1111/ene.70103}
}
Start for free →